SG191602A1 - Reoviruses having modified sequences - Google Patents

Reoviruses having modified sequences Download PDF

Info

Publication number
SG191602A1
SG191602A1 SG2013040027A SG2013040027A SG191602A1 SG 191602 A1 SG191602 A1 SG 191602A1 SG 2013040027 A SG2013040027 A SG 2013040027A SG 2013040027 A SG2013040027 A SG 2013040027A SG 191602 A1 SG191602 A1 SG 191602A1
Authority
SG
Singapore
Prior art keywords
leu
ser
ala
val
asp
Prior art date
Application number
SG2013040027A
Other languages
English (en)
Inventor
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39758956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG191602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of SG191602A1 publication Critical patent/SG191602A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG2013040027A 2007-03-12 2008-03-11 Reoviruses having modified sequences SG191602A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89442507P 2007-03-12 2007-03-12
US98956807P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
SG191602A1 true SG191602A1 (en) 2013-07-31

Family

ID=39758956

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013040027A SG191602A1 (en) 2007-03-12 2008-03-11 Reoviruses having modified sequences

Country Status (16)

Country Link
US (5) US7803385B2 (enExample)
EP (2) EP2952583A1 (enExample)
JP (1) JP5577103B2 (enExample)
KR (1) KR101647843B1 (enExample)
CN (1) CN103710359A (enExample)
AR (1) AR066395A1 (enExample)
AU (1) AU2008226291B2 (enExample)
CA (1) CA2678721C (enExample)
DK (1) DK2132315T3 (enExample)
ES (1) ES2548442T3 (enExample)
IL (4) IL200353A (enExample)
MX (2) MX2009009598A (enExample)
SG (1) SG191602A1 (enExample)
TW (1) TW200904979A (enExample)
WO (1) WO2008110004A1 (enExample)
ZA (1) ZA200905951B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
SG191602A1 (en) 2007-03-12 2013-07-31 Oncolytics Biotech Inc Reoviruses having modified sequences
AU2008316276A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
MX2010014555A (es) * 2008-06-26 2011-04-27 Ceva Sante Animale Sa Reoviridae aviar unico.
FR2939807B1 (fr) * 2008-12-11 2010-12-17 Biomerieux Sa Nouveau reovirus isole, procedes et kits de detection
EP2482825B1 (en) 2009-10-02 2016-11-23 The Trustees of Columbia University in the City of New York Piscine reovirus diagnostic compositions
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
MX373096B (es) * 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.
EA201391605A1 (ru) * 2011-04-29 2014-02-28 Онколитикс Байотек Инк. Способы очистки вирусов с использованием гельпроникающей хроматографии
ES2796950T3 (es) 2013-11-15 2020-11-30 Oncolytics Biotech Inc Virus oncolíticos y regímenes reforzados para tratamiento de cáncer
US9660989B1 (en) 2014-01-31 2017-05-23 Google Inc. Internet-wide identity management widget
WO2017141942A1 (ja) 2016-02-16 2017-08-24 国立大学法人大阪大学 線維化を治療するための医薬組成物
WO2019237063A1 (en) * 2018-06-07 2019-12-12 Emory University Modified reoviruses, particles, and uses in treating proliferative disorders
KR102401077B1 (ko) 2019-01-25 2022-05-24 바이로큐어 주식회사 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물
US20220193220A1 (en) * 2019-05-03 2022-06-23 Kansas State University Research Foundation Immunogenic compositions for novel reassortant mammalian ortheovirus from pigs
CN116917468A (zh) * 2020-12-22 2023-10-20 百洛克株式会社 新型修饰的呼肠孤病毒及其用途
JP2024500164A (ja) * 2020-12-22 2024-01-04 バイロキュア インコーポレイテッド 新規な改変レオウイルス及びその用途
US20250154204A1 (en) * 2021-09-24 2025-05-15 Virocure, Inc. Novel reovirus-based vaccine platform and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
ES2445704T3 (es) 2000-11-09 2014-03-04 Oncolytics Biotech Inc. Métodos para el tratamiento de trastornos celulares proliferativos
WO2002043647A2 (en) 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
IL157304A0 (en) 2001-03-16 2004-02-19 Oncolytics Biotech Inc Method of extracting virus from cell culture
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
EP1775343A4 (en) * 2004-06-24 2007-11-14 Dnavec Research Inc ANTITUM-AGENT WITH DENDRITIC CELL WITH THE TRANSFECTED RNA VIRUS
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US20100086522A1 (en) 2006-07-18 2010-04-08 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
SG191602A1 (en) 2007-03-12 2013-07-31 Oncolytics Biotech Inc Reoviruses having modified sequences
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
CA2819236A1 (en) * 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
MX373096B (es) * 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.

Also Published As

Publication number Publication date
KR101647843B1 (ko) 2016-08-11
US10596260B2 (en) 2020-03-24
JP5577103B2 (ja) 2014-08-20
AU2008226291A2 (en) 2009-10-08
IL221701A0 (en) 2012-10-31
AU2008226291A1 (en) 2008-09-18
CA2678721C (en) 2018-02-13
HK1132761A1 (en) 2010-03-05
US11246930B2 (en) 2022-02-15
AU2008226291B2 (en) 2014-01-16
JP2010520758A (ja) 2010-06-17
US20090035278A2 (en) 2009-02-05
US7803385B2 (en) 2010-09-28
US20110020288A1 (en) 2011-01-27
US20200237917A1 (en) 2020-07-30
US20140186301A1 (en) 2014-07-03
TW200904979A (en) 2009-02-01
MX346950B (es) 2017-04-06
ES2548442T3 (es) 2015-10-16
EP2132315A1 (en) 2009-12-16
US10039827B2 (en) 2018-08-07
EP2132315B1 (en) 2015-07-15
IL221700A0 (en) 2012-10-31
EP2132315A4 (en) 2011-10-05
ZA200905951B (en) 2010-11-24
IL221702A0 (en) 2012-10-31
MX2009009598A (es) 2009-09-21
CN103710359A (zh) 2014-04-09
US20080226602A1 (en) 2008-09-18
WO2008110004A1 (en) 2008-09-18
EP2952583A1 (en) 2015-12-09
AR066395A1 (es) 2009-08-19
IL200353A (en) 2017-07-31
US20180344853A1 (en) 2018-12-06
US8691241B2 (en) 2014-04-08
DK2132315T3 (en) 2015-10-19
IL200353A0 (en) 2011-08-01
CA2678721A1 (en) 2008-09-18
KR20090125103A (ko) 2009-12-03

Similar Documents

Publication Publication Date Title
US11246930B2 (en) Reoviruses having modified sequences
AU2008253505B2 (en) Mutant reoviruses and methods of making and using
EP1309672A1 (en) Method of producing infectious reovirus
TW200951143A (en) Modulating interstitial pressure and oncolytic viral delivery and distribution
EP1424897A2 (en) Compositions and methods for treatment of cancer
AU2013201835A1 (en) Reoviruses having modified sequences
CN109419818B (zh) 一种用于治疗肿瘤的埃可病毒
CN101627122A (zh) 具有修饰的序列的呼肠孤病毒
AU2009253683B2 (en) Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
CN103882057B (zh) 携带p21ras单链抗体基因肿瘤特异性腺病毒载体的构建及其应用
HK1132761B (en) Reoviruses having modified sequences
CN113667016A (zh) 一种构建冠状病毒抗体的平台
HK1136006B (en) Mutant reoviruses and methods of making and using